Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
979 3 |
Ultima descărcare din IBN: 2024-03-21 15:30 |
SM ISO690:2012 ŞCIUCA, Svetlana, NEAMŢU, Liuba. Importanţa etiopatogenică a tratamentului antibacterian cu macrolide în infecţia cu mycoplasma în pneumologia pediatrică. In: Arta Medica , 2010, nr. 2(41), pp. 43-46. ISSN 1810-1852. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Arta Medica | ||||||
Numărul 2(41) / 2010 / ISSN 1810-1852 /ISSNe 1810-1879 | ||||||
|
||||||
Pag. 43-46 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
In the study participated 36 children aged 5 month to 7 years, all suffering from respiratory pathology. Aim of our study was to appreciate
clinical manifestations, specific immunological changes, and abnormalities in humoral immunity and determination of the efficiency of
antibacterial treatment with Azithromycin in pediatric pneumology. The level of IgA (0.52±0.09 g/l) and IgG (8.43±0.6 g/l) was decreased
in comparison to the values of IgA and IgG in healthy children (IgA 1.18±0.05g/l, IgG 1.18±0.05g/l). But the level of IgM (1.41±0.1 g/l)
in Mycoplasma-positive group was higher than in healthy children (1.27±0.03 g/l). The treatment with Azithromycin shows benefits in
pulmonary auscultative manifestations and X-ray, decreasing the levels of specific Mycoplasma immunoglobulins and positive dynamics
in humoral immunity. |
||||||
Cuvinte-cheie Mycoplasma infection, bronhopulmonary affection, Azithromycin |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-9373</cfResPublId> <cfResPublDate>2010-06-01</cfResPublDate> <cfVol>41</cfVol> <cfIssue>2</cfIssue> <cfStartPage>43</cfStartPage> <cfISSN>1810-1852</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/9373</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Importanţa etiopatogenică a tratamentului antibacterian cu macrolide în infecţia cu mycoplasma în pneumologia pediatrică</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>Mycoplasma infection; bronhopulmonary affection; Azithromycin</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'>In the study participated 36 children aged 5 month to 7 years, all suffering from respiratory pathology. Aim of our study was to appreciate clinical manifestations, specific immunological changes, and abnormalities in humoral immunity and determination of the efficiency of antibacterial treatment with Azithromycin in pediatric pneumology. The level of IgA (0.52±0.09 g/l) and IgG (8.43±0.6 g/l) was decreased in comparison to the values of IgA and IgG in healthy children (IgA 1.18±0.05g/l, IgG 1.18±0.05g/l). But the level of IgM (1.41±0.1 g/l) in Mycoplasma-positive group was higher than in healthy children (1.27±0.03 g/l). The treatment with Azithromycin shows benefits in pulmonary auscultative manifestations and X-ray, decreasing the levels of specific Mycoplasma immunoglobulins and positive dynamics in humoral immunity.</cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>В работу было включено 36 детей, в возрасте от 5 месяцев до 7 лет, с бронхолегочной патологией, для оценки клинической картины, специфической серологической характеристики, состояния гуморальной иммунной системы и определения эффективности антибактериального лечения Азитромицином при микоплазменной инфекции в педиатрической пульмонологии. В группе детей с микоплазменной инфекцией уровень сывороточного IgA (0,55±0,09 г/л) и IgG (8,43±0,6 г/л) снижен по отношению к возрастным нормативам здоровых детей (IgA 1,18±0,05г/л, IgG 1,18±0,05г/л), а уровень IgM (1,41±0,1 г/л) повышен сравнительно возрастных стандартов (1,27±0,03 г/л). Применение Азитромицина способствовало улучшению аускультативных и рентгенологических данных, снижению уровня специфических иммуноглобулинов и восстановления показателей гуморального иммунитета.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11781</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29682</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11781</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11781-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> <cfFamilyNames>Щука</cfFamilyNames> <cfFirstNames>Светлана</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29682</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29682-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-06-01T24:00:00</cfStartDate> <cfFamilyNames>Neamtu</cfFamilyNames> <cfFirstNames>Liuba</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>